November 2007 Oncology News International

Jesus Corral Jaime, MD, reviews real-world survival and response data for cemiplimab monotherapy from the CEMI-LUNG study.

At the Big Ten CRC Summit, VK Gadi, MD, PhD, explained why functional drug testing and genomic profiling should be used together in oncology.

First-line pembrolizumab monotherapy did not significantly improve overall survival vs carboplatin plus paclitaxel at the first analysis in dMMR advanced or recurrent endometrial cancer.

Findings from the phase 1 KANDLELIT-001 study support further investigation of calderasib plus pembrolizumab in KRAS G12C-mutated metastatic NSCLC.

Sacituzumab tirumotecan improved survival vs chemotherapy in patients with advanced or recurrent endometrial cancer after platinum and immunotherapy.

Oral vitamin C improved OS in patients with CCUS or lower-risk myeloid malignancies in the EVITA trial despite missing the clonal growth primary end point.

In KEYNOTE-412, early ctDNA clearance was linked with better survival with pembrolizumab plus chemoradiotherapy in HPV-negative head and neck cancer.

Phase 3 TALAPRO-3 data support the FDA approval of talazoparib/enzalutamide in HRR gene-altered metastatic androgen pathway modulation-naïve or -sensitive prostate cancer.